Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.
Clostridium difficile
antibody
bile salt stability
developability
oral administration
single‐domain antibody
Journal
Protein science : a publication of the Protein Society
ISSN: 1469-896X
Titre abrégé: Protein Sci
Pays: United States
ID NLM: 9211750
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
02
05
2024
received:
11
12
2023
accepted:
08
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
ppublish
Résumé
Single-domain antibodies (sdAbs), such as V
Substances chimiques
Single-Domain Antibodies
0
Bacterial Toxins
0
Bacterial Proteins
0
toxB protein, Clostridium difficile
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e5035Subventions
Organisme : Innovation Fund Denmark
ID : 0174-00002B
Organisme : Innovation Fund Denmark
ID : 1044-00106B
Informations de copyright
© 2024 The Author(s). Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society.
Références
Adelman SA, Doll JD. Generalized Langevin equation approach for atom/solid‐surface scattering: general formulation for classical scattering off harmonic solids. J Chem Phys. 1976;64(6):2375–2388.
Aguirre AM, Yalcinkaya N, Wu Q, Swennes A, Tessier ME, Roberts P, et al. Bile acid‐independent protection against Clostridioides difficile infection. PLoS Pathog. 2021;17(10):e1010015.
Ahmadi S, Pucca MB, Jürgensen JA, Janke R, Ledsgaard L, Schoof EM, et al. An in vitro methodology for discovering broadly‐neutralizing monoclonal antibodies. Sci Rep. 2020;10(1):1–7.
Aktories K, Schwan C, Jank T. Clostridium difficile toxin biology. Annu Rev Microbiol. 2017;71:281–307.
Andersen HC. Rattle: a “velocity” version of the shake algorithm for molecular dynamics calculations. J Comput Phys. 1983;52(1):24–34.
Andersen KK, Strokappe NM, Hultberg A, Truusalu K, Smidt I, Mikelsaar RH, et al. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli that produce single‐domain antibodies. Infect Immun. 2016;84(2):395–406.
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies. FEBS Lett. 1997;414(3):521–526.
Ausserwöger H, Schneider MM, Herling TW, Arosio P, Invernizzi G, Knowles TPJ, et al. Non‐specificity as the sticky problem in therapeutic antibody development. Nat Rev Chem. 2022;6(12):844–861.
Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee GR, et al. Accurate prediction of protein structures and interactions using a three‐track neural network. Science. 2021;373(6557):871–876.
Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, et al. Predicting antibody developability profiles through early stage discovery screening. mAbs. 2020;12(1):1743053.
Bayly CI, Merz KM, Ferguson DM, Cornell WD, Fox T, Caldwell JW, et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc. 1995;117(19):5179–5197.
Behring E. Untersuchungen über das Zustandekommen der Diphtherie‐Immunität und der Tetanus‐Immunität bei Thieren. Deutsch Med Wochenshr. 1890;16(49):1113–1114.
Berendsen HJC, Postma JPM, Van Gunsteren WF, Dinola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81(8):3684–3690.
Beuers U, Pusl T. Bile salts and their metabolism. Encyclopedia of Biological Chemistry. Amsterdam: Elsevier; 2004. p. 159–163.
Brown C, Leijon F, Bulone V. Radiometric and spectrophotometric in vitro assays of glycosyltransferases involved in plant cell wall carbohydrate biosynthesis. Nat Prot. 2012;7(9):1634–1650.
Carter GP, Chakravorty A, Nguyen TAP, Mileto S, Schreiber F, Li L, et al. Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio. 2015;6(3):e00551.
Case DA, Aktulga HM, Belfon K, Cerutti DS, Cisneros GA, Cruzeiro VWD, et al. AmberTools. J Chem Inf Model. 2023;63(20):6183–6191.
Chen P, Lam K h, Liu Z, Mindlin FA, Chen B, Gutierrez CB, et al. Structure of the full‐length Clostridium difficile toxin B. Nat Struct Mol Biol. 2019;26(8):712–719.
Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Exp. 2018;18(2):71–87.
Chung SY, Schöttelndreier D, Tatge H, Fühner V, Hust M, Beer LA, et al. The conserved Cys‐2232 in Clostridioides difficile toxin B modulates receptor binding. Front Microbiol. 2018;9:410252.
Cremers CM, Knoefler D, Vitvitsky V, Banerjee R, Jakob U. Bile salts act as effective protein‐unfolding agents and instigators of disulfide stress in vivo. PNAS. 2014;111(16):E1610–E1619.
Darden T, York D, Pedersen L. Particle mesh Ewald: an N·log(N) method for Ewald sums in large systems. J Chem Phys. 1993;98(12):10089–10092.
D'Auria KM, Bloom MJ, Reyes Y, Gray MC, Van Opstal EJ, Papin JA, et al. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types. BMC Microbiol. 2015;15(1):1–10.
Debatis M, Danz H, Tremblay JM, Gaspie K, Kudej RK, Vigdorovich V, et al. Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single‐domain antibodies. PLoS One. 2023;18(11):e0291937.
Di Ciaula A, Garruti G, Baccetto RL, Molina‐Molina E, Bonfrate L, Wang DQH, et al. Bile acid physiology. Ann Hepatol. 2017;16:S4–S14.
doVale A, Cabanes D, Sousa S. Bacterial toxins as pathogen weapons against phagocytes. Front Microbiol. 2016;7:172814.
Drozdowski B, Zhou Y, Kline B, Spidel J, Chan YY, Albone E, et al. Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B. J Immune Based Therap Vaccines. 2010;8(1):1–9.
El Hage K, Hédin F, Gupta PK, Meuwly M, Karplus M. Valid molecular dynamics simulations of human hemoglobin require a surprisingly large box size. eLife. 2018;7:e35560.
Faulstich H, Kirchner K, Derenzini M. Strongly enhanced toxicity of the mushroom toxin α‐amanitin by an amatoxin‐specific Fab or monoclonal antibody. Toxicon. 1988;26(5):491–499.
Fernández‐Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, et al. Assessing developability early in the discovery process for novel biologics. mAbs. 2023;15(1):2171248.
Ferrara F, D'Angelo S, Gaiotto T, Naranjo L, Tian H, Gräslund S, et al. Recombinant renewable polyclonal antibodies. mAbs. 2015;7(1):32.
Fiil BK, Thrane SW, Pichler M, Kittilä T, Ledsgaard L, Ahmadi S, et al. Orally active bivalent VHH construct prevents proliferation of F4+ enterotoxigenic Escherichia coli in weaned piglets. iScience. 2022;25(4):104003.
Garcia‐Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, et al. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes. Toxins. 2018;10(3):105.
Gavrilaș S, Ursachi CȘ, Perța‐Crișan S, Munteanu FD. Recent trends in biosensors for environmental quality monitoring. Sensors. 2022;22(4):1513.
Ghazaei C. Advances in the study of bacterial toxins, their roles and mechanisms in pathogenesis. Malays J Med Sci. 2022;29(1):4–17.
Goldman ER, Liu JL, Zabetakis D, Anderson GP. Enhancing stability of camelid and shark single domain antibodies: an overview. Front Immunol. 2017;8:1.
Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, et al. Human anti‐self antibodies with high specificity from phage display libraries. EMBO J. 1993;12(2):725–734.
Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):1–13.
Hamilton JP, Xie G, Raufman JP, Hogan S, Griffin TL, Packard CA, et al. Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):256–263.
Harmsen MM, Van Solt CB, Van Zijderveld‐Van Bemmel AM, Niewold TA, Van Zijderveld FG. Selection and optimization of proteolytically stable llama single‐domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol. 2006;72(3):544–551.
Harris B. Exploiting antibody‐based technologies to manage environmental pollution. Trends Biotechnol. 1999;17(7):290–296.
He X, Sun X, Wang J, Wang X, Zhang Q, Tzipori S, et al. Antibody‐enhanced, fc gamma receptor‐mediated endocytosis of Clostridium difficile toxin a. Infect Immun. 2009;77(6):2294–2303.
Hortigüela MJ, Wall JG. Improved detection of domoic acid using covalently immobilised antibody fragments. Marine Drugs. 2013;11(3):881–895.
Hub JS, De Groot BL, Grubmüller H, Groenhof G. Quantifying artifacts in Ewald simulations of inhomogeneous systems with a net charge. J Chem Theory Comput. 2014;10(1):381–390.
Hussack G, Arbabi‐Ghahroudi M, Van Faassen H, Songer JG, Ng KKS, MacKenzie R, et al. Neutralization of Clostridium difficile toxin A with single‐domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286(11):8961–8976.
Hussack G, Hirama T, Ding W, MacKenzie R, Tanha J. Engineered single‐domain antibodies with high protease resistance and thermal stability. PLoS One. 2011;6(11):e28218.
Hutton ML, Cunningham BA, Mackin KE, Lyon SA, James ML, Rood JI, et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep. 2017;7(1):1–13.
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926–935.
Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 2018;27(1):112–128.
Kang TH, Seong BL. Solubility, stability, and avidity of recombinant antibody fragments expressed in microorganisms. Front Microbiol. 2020;11:552011.
Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile‐associated disease in a hamster model of infection. Infect Immun. 1998;66(5):2018–2025.
Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microb. 2023;15(1):2172671.
Laustsen AH, Karatt‐Vellatt A, Masters EW, Arias AS, Pus U, Knudsen C, et al. In vivo neutralization of dendrotoxin‐mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nat Commun. 2018;9(1):1–9.
Lee Y, Lim WI, Bloom CI, Moore S, Chung E, Marzella N. Bezlotoxumab (Zinplava) for Clostridium difficile infection: the first monoclonal antibody approved to prevent the recurrence of a bacterial infection. Pharm Ther. 2017;42(12):735–738.
Liu J, Kothe M, Zhang JJ, Oloo E, Stegalkina S, Mundle ST, et al. Novel structural insights for a pair of monoclonal antibodies recognizing non‐overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B. Curr Res Struct Biol. 2022;4:96–105.
Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991;59(6):2215–2218.
Maffey L, Vega CG, Miño S, Garaicoechea L, Parreño V. Anti‐VP6 VHH: an experimental treatment for rotavirus A‐associated disease. PLoS One. 2016;11(9):e0162351.
Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696–3713.
Mansfield MJ, Tremblay BJM, Zeng J, Wei X, Hodgins H, Worley J, et al. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination‐driven evolution and diversification of toxin A and B. PLoS Pathog. 2020;16(12):e1009181.
Minekus M. The TNO gastro‐intestinal model (TIM). The impact of food bioactives on health: in vitro and ex vivo models. Cham: Springer; 2015. p. 37–46.
Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022;19(6):679–682.
Morens DM. Antibody‐dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis. 1994;19(3):500–512.
Nair PP. Bile–salt–protein interactions. The bile acids: chemistry, physiology, and metabolism. Boston: Springer; 1976. p. 29–52.
Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biol Targets Ther. 2018;12:11.
Nielsen LS, Baer A, Müller C, Gregersen K, Mønster NT, Rasmussen SK, et al. Single‐batch production of recombinant human polyclonal antibodies. Mol Biotechnol. 2010;45(3):257–266.
Orrell KE, Zhang Z, Sugiman‐Marangos SN, Melnyk RA. Clostridium difficile toxins A and B: receptors, pores, and translocation into cells. Crit Rev Biochem Mol Biol. 2017;52(4):461–473.
Petersson M, Thrane SW, Gram L, Muyldermans S, Laustsen AH. Orally delivered single‐domain antibodies against gastrointestinal pathogens. Trends Biotechnol. 2023;41(7):875–886.
Pitiot A, Heuzé‐Vourc'h N, Sécher T. Alternative routes of administration for therapeutic antibodies—state of the art. Antibodies. 2022;11(3):56.
Pruitt RN, Chambers MG, Ng KKS, Ohi MD, Lacy DB. Structural organization of the functional domains of Clostridium difficile toxins A and B. PNAS. 2010;107(30):13467–13472.
Reilly RM, Domingol R, Sandhu J. Oral delivery of antibodies future pharmacokinetic trends. Clin Pharmacokinet. 1997;32(4):313–323.
Roberts AK, Harris HC, Smith M, Giles J, Polak O, Buckley AM, et al. A novel, orally delivered antibody therapy and its potential to prevent Clostridioides difficile infection in pre‐clinical models. Front Microbiol. 2020;11:578903.
Rodríguez‐Rodríguez ER, Olamendi‐Portugal T, Serrano‐Posada H, Arredondo‐López JN, Gómez‐Ramírez I, Fernández‐Taboada G, et al. Broadening the neutralizing capacity of a family of antibody fragments against different toxins from Mexican scorpions. Toxicon. 2016;119:52–63.
Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084–3095.
Rouha H, Weber S, Janesch P, Maierhofer B, Gross K, Dolezilkova I, et al. Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies. Virulence. 2018;9(1):231–247.
Rutten L, De Haard H, Verrips T. Improvement of proteolytic stability through in silico engineering. Methods Mol Biol. 2012;911:373–381.
Salomon‐Ferrer R, Case DA, Walker RC. An overview of the Amber biomolecular simulation package. WIREs Comput Mol Sci. 2013;3(2):198–210.
Sánchez‐Zuno GA, Matuz‐Flores MG, González‐Estevez G, Nicoletti F, Turrubiates‐Hernández FJ, Mangano K, et al. A review: antibody‐dependent enhancement in COVID‐19: the not sofriendly side of antibodies. Int J Immunopathol Pharmacol. 2021;35:1–15.
Schmidt DJ, Beamer G, Tremblay JM, Steele JA, Kim HB, Wang Y, et al. A tetraspecific VHH‐based neutralizing antibody modifies disease outcome in three animal models of Clostridium difficile infection. Clin Vaccine Immunol. 2016;23(9):774–784.
Shinozaki N, Hashimoto R, Fukui K, Uchiyama S. Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities. Sci Rep. 2017;7(1):1–11.
Sørensen CV, Ledsgaard L, Wildenauer HHK, Dahl CH, Ebersole TW, Bohn MF, et al. Cross‐reactivity trends when selecting scFv antibodies against snake toxins using a phage display‐based cross‐panning strategy. Sci Rep. 2023;13(1):1–10.
Stijlemans B, Conrath K, Cortez‐Retamozo V, Van Xong H, Wyns L, Senter P, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem. 2004;279(2):1256–1261.
Tam J, Icho S, Utama E, Orrell KE, Gómez‐Biagi RF, Theriot CM, et al. Intestinal bile acids directly modulate the structure and function of C. difficile TcdB toxin. Proc Natl Acad Sci U S A. 2020;117(12):6792–6800.
Thuenemann EC, Giuseppina GM, Rich GT, Faulks RM. Dynamic gastric model (DGM). The impact of food bioactives on health: in vitro and ex vivo models. Cham: Springer; 2015. p. 47–59.
Torres VVL, Coggon CF, Wells TJ. Antibody‐dependent enhancement of bacterial disease: prevalence, mechanisms, and treatment. Infect Immun. 2021;89(4):e00054‐21.
Tsubokura K, Berndtson E, Bogstedt A, Kaijser B, Kim M, Ozeki M, et al. Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens. Clin Exp Immunol. 2003;108(3):451–455.
Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Žídek A, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596(7873):590–596.
Van Dissel JT, De Groot M, Hensgens CMH, Numan S, Kuijper EJ, Veldkamp P, et al. Bovine antibody‐enriched whey to aid in the prevention of a relapse of Clostridium difficile‐associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol. 2005;54(2):197–205.
Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh‐Ghassabeh G, Muyldermans S. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. Methods Mol Biol. 2012;907:145–176.
Wallnoefer HG, Handschuh S, Liedl KR, Fox T. Stabilizing of a globular protein by a highly complex water network: a molecular dynamics simulation study on factor Xa. J Phys Chem B. 2010;114(21):7405–7412.
Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722–1760.
Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe. 2016;41:44–50.
Wolf Pérez AM, Lorenzen N, Vendruscolo M, Sormanni P. Assessment of therapeutic antibody developability by combinations of in vitro and in silico methods. Methods Mol Biol. 2022;2313:57–113.
Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, et al. A novel multivalent, single‐domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis. 2014;210(6):964–972.
Zeng H, Umar S, Rust B, Lazarova D, Bordonaro M. Secondary bile acids and short chain fatty acids in the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer. Int J Mol Sci. 2019;20(5):1214.
Zhao H, Tasch M, Dodds M, Gewe M, Martinez A, Hutton M, et al. Using antibody synergy to engineer a high potency biologic cocktail against C. difficile. bioRxiv. 2021. https://doi.org/10.1101/2021.12.21.473715
Zhuang S, Li Q, Cai L, Wang C, Lei X. Chemoproteomic profiling of bile acid interacting proteins. ACS Central Sci. 2017;3(5):501–509.